Coadministration with pantoprazole has not been studied. Significant decreases in rilpivirine plasma concentrations are expected due to reduced absorption due to gastric pH increase. Rilpivirine must not be used in combination with proton pump inhibitors as co-administration is likely to result in loss of therapeutic effect of rilpivirine.

 

Coadministration is contraindicated due to the potential for significant decreases in rilpivirine plasma concentrations due to gastric pH increase, which may result in loss of virologic response.